Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
60 hedge funds and large institutions have $76.5M invested in Sierra Oncology, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 15 closing their positions.
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
14% less funds holding
Funds holding: 70 → 60 (-10)
46% less capital invested
Capital invested by funds: $141M → $76.5M (-$64.9M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$4.5M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.07M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.24M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.1M |
| 5 |
Renaissance Technologies
New York
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.22M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.06M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.95M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.37M |
| 5 |
Millennium Management
New York
|
-$1.88M |
SRRA Hedge Fund Activity: Q3 2018 in Review
60 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2018, worth a combined $76.5M — down 46% from $141M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SRRA and 5 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Broadfin Capital, adding an estimated $4.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.22M sold.
- 60 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2018, down from 70 in Q2 2018.
- Funds reported $76.5M of Sierra Oncology, Inc. Common Stock stock for Q3 2018, down 46% quarter-over-quarter.
- 5 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2018 and 15 closed out, a net change of -10 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2018 was Broadfin Capital, an estimated $4.5M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2018 was Deerfield Management, an estimated $5.22M sold.
Based on aggregated 13F filings for Q3 2018.